Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 12/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332899 | 0.91 | ATF4 (0.41) | ATF4NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL25963212 | 0.89 | ATF4 (0.51) | ATF4 | |
| SCHEMBL23332913 | 0.89 | ATF4 (0.51) | ATF4SCN9AHSD17B14SCN10A | |
| SCHEMBL23333261 | 0.87 | ATF4 (0.53) | ATF4SCN9ASCN10A | |
| SCHEMBL21389922 | 0.87 | ATF4 (0.53) | ATF4SCN9ASCN10A | |
| SCHEMBL23294698 | 0.87 | ATF4 (0.53) | ATF4SCN9ASCN10A | |
| SCHEMBL23332874 | 0.80 | ATF4 (0.37) | ATF4SCN9A | |
| SCHEMBL23294632 | 0.79 | ATF4 (0.54) | ATF4 | |
| SCHEMBL21390156 | 0.79 | ATF4 (0.54) | ATF4 | |
| SCHEMBL23332909 | 0.79 | ATF4 (0.38) | ATF4NPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885NPC1 1838/4885NFKB1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.